<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Apomorphine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Apomorphine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Apomorphine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10800" href="/d/html/10800.html" rel="external">see "Apomorphine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F136184"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Apokyn;</li>
<li>Kynmobi Titration Kit [DSC];</li>
<li>Kynmobi [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865954"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kynmobi [DSC];</li>
<li>Movapo [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F136203"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F136187"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Beginning antiemetic therapy (eg, trimethobenzamide) is recommended 3 days prior to initiation; continue only as long as necessary, and generally no longer than 2 months, due to increased risk of adverse events. Apomorphine is intended to be used as adjunctive therapy with other anti-Parkinson agents.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5ced66f-10fe-4ef0-a7d6-60b23cbfd998">Parkinson disease, "off" episode</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, "off" episode:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual film:</b>
<b>Note:</b> Determine starting dose when patient is in an "off" state and in a setting where a health care provider can monitor blood pressure and pulse. In clinical trials, to achieve an "off" state, the morning dose of carbidopa/levodopa (or any adjunctive Parkinson disease medications) was withheld and any Parkinson disease medications were avoided after midnight the night before. If response insufficient but dose tolerated, patient should resume usual Parkinson medications and return to health care provider in an "off" state to reinitiate at the next dose increment.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 10 mg as needed at intervals ≥2 hours for "off" episodes up to a maximum of 5 doses per day; may increase dose in 5 mg increments within 3 days based on response and tolerability up to a maximum single dose of 30 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial test dose 0.1 mL (1 mg) or 0.2 mL (2 mg), <b>medical supervision required; see "Note."</b> Consider initiating therapy at 0.1 mL (1 mg) as an alternative to trimethobenzamide therapy to reduce the incidence of nausea and vomiting. Subsequent dosing is based on both tolerance and response to initial test dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates and responds to 0.1 mL (1 mg) test dose: Starting dose: 0.1 mL (1 mg) as needed; may increase dose in 0.1 mL (1 mg) increments every few days; maximum dose: 0.6 mL (6 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates or does not tolerate and responds to 0.2 mL (2 mg) test dose: Starting dose: 0.2 mL (2 mg) as needed; may increase dose in 0.1 mL (1 mg) increments every few days; patients who do not tolerate the 0.2 mL (2 mg) test dose may need the dose increased slowly; maximum dose: 0.6 mL (6 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates but does not respond to 0.1 mL (1 mg) test dose: Second test dose: 0.2 mL (2 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates but does not respond to 0.2 mL (2 mg) test dose: Second test dose: 0.4 mL (4 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates and responds to 0.4 mL (4 mg) test dose: Starting dose: 0.3 mL (3 mg), as needed for “off” episodes; may increase dose in 0.1 mL (1 mg) increments every few days; maximum dose: 0.6 mL (6 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient does not tolerate 0.4 mL (4 mg) test dose: Third test dose: 0.3 mL (3 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">If patient tolerates 0.3 mL (3 mg) test dose: Starting dose: 0.2 mL (2 mg) as needed for “off” episodes; after a few days, may increase dose up to 0.3 mL (3 mg). Medically supervise for any subsequent dose increases &gt;0.3 mL (3 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>If therapy is interrupted for &gt;1 week, restart at 0.2 mL (2 mg) and gradually titrate dose.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Medical supervision is required for all test doses with standing and supine blood pressure monitoring predose and 20-, 40-, and 60 minutes postdose (and after 60 minutes, if there is significant hypotension at 60 minutes). If subsequent test doses are required, wait &gt;2 hours before another test dose is given; next test dose should be timed with another “off” episode. If a single dose is ineffective for a particular “off” episode, then a second dose should not be given. The average dosing frequency was 3 times/day in the development program with limited experience in dosing &gt;5 times/day, single doses &gt;0.6 mL (6 mg), and with total daily doses &gt;2 mL (20 mg).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991753"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sublingual film:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial test dose: 0.1 mL (1 mg); Starting dose: 0.1 mL (1 mg) as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988858"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sublingual film:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary; use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F136188"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use with caution; adverse effects (confusion and hallucinations), some serious, are reported more frequently in patients ≥65 years of age. Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F136157"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported percentages are for the SUBQ product unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (≤15%), chest pain (≤15%), chest pressure (≤15%), hypotension (SUBQ: ≤11%; sublingual film: ≤4%), orthostatic hypotension (SUBQ: ≤20%; sublingual film: ≤4%), syncope (SUBQ: ≤11%; sublingual film: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (SUBQ: ≤30%; sublingual film: 21% to 28%; can be severe nausea; can occur with antiemetic pretreatment), oral paresthesia (sublingual film: ≤13%), vomiting (SUBQ: ≤30%; sublingual film: 4% to 7%; can be severe vomiting; can occur with antiemetic pretreatment)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (5% to 26%; bruising at injection site [16%], injection-site granuloma [4%], injection-site pruritus [2%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (SUBQ: ≤20%; sublingual film: 9% to 11%), drowsiness (SUBQ: 35%; sublingual film: 11% to 13%), falling (SUBQ: 30%; sublingual film: 4% to 6%), hallucination (SUBQ: ≤14%, sublingual film: ≤6%), yawning (SUBQ: 40%; sublingual film: 4% to 12% [Olanow 2020])</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (SUBQ: 24% to 35%; sublingual film: 1% [Olanow 2020])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal edema (sublingual film: 1% to 15%), oropharyngeal pain (sublingual film: ≤13%), rhinorrhea (SUBQ: 20%; sublingual film: 6% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (≤4%), edema (≤10%), heart failure (≥5%), presyncope (sublingual film: ≤4%), swelling of extremities (≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≥5%), ecchymoses (≥5%), hyperhidrosis (sublingual film: 4% to 6%), urticaria (sublingual film: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (≥5%), diarrhea (≥5%), oral mucosa ulcer (sublingual film: ≤7%), oral mucosal erythema (sublingual film: 4% to 7%), stomatitis (sublingual film: ≤7%), xerostomia (sublingual film: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial swelling (sublingual film: ≤6%), hypersensitivity reaction (sublingual film: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (≥5%), %), asthenia (≥5%), confusion (SUBQ: ≤10%; sublingual film: ≤6%), delusion (sublingual film: ≤6%), depression (≥5%), disorientation (sublingual film: ≤6%), exacerbation of Parkinson disease (≥5%), fatigue (SUBQ: ≥5%; sublingual film: 3% to 7%), headache (SUBQ: ≥5%; sublingual film: 6% to 8%), insomnia (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥5%), back pain (≥5%), limb pain (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≥5%), pneumonia (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration (sublingual film: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Genitourinary: Priapism</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (dose related)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Colosimo 1994; Frankel 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, behavioral changes, impulse control disorder (including, increased libido, pathological gambling), mental status changes, paranoid ideation, psychosis (acute), sudden onset of sleep</p></div>
<div class="block coi drugH1Div" id="F136170"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to apomorphine, any component of the formulation, or to a sulfite; concomitant use with 5-HT<sub>3</sub> antagonists.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with antihypertensives or vasodilators (Movapo); severe hepatic or renal impairment.</p></div>
<div class="block war drugH1Div" id="F136155"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Severe nausea and vomiting may occur. Pretreatment with antiemetic (eg, trimethobenzamide) is necessary and should be started 3 days prior to initiation of therapy and continued only as long as necessary to control nausea/vomiting, and generally no longer than 2 months. Trimethobenzamide increases the risk of somnolence, dizziness, and falls. Avoid use of antidopaminergic antiemetic agents (eg, promethazine, prochlorperazine, chlorpromazine, metoclopramide, haloperidol).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hallucinations/psychosis: May cause hallucinations or psychotic-like behavior or thoughts (eg, paranoia, delusions, confusion, disorientation, aggression, agitation, delirium) which may be severe; avoid in patients with major psychotic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Hemolytic anemia, requiring hospitalization and including severe anemia, angina, and dyspnea, has been reported and may occur at any time after treatment; most cases included a positive direct antiglobulin test (Coombs test) suggesting a potential immune-mediated hemolysis. If hemolytic anemia occurs, consider discontinuing treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including angioedema or anaphylaxis) to apomorphine or its sulfite component may occur. If a hypersensitivity reaction to apomorphine occurs, discontinue and do not restart.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impulse control disorders: Has been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), binge eating, and/or other intense urges. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension/syncope: May cause orthostatic hypotension, especially during dose escalation, and syncope. Parkinson disease patients appear to have an impaired capacity to respond to a postural challenge. The hypotensive effects of apomorphine are exacerbated by concomitant ethanol consumption and sublingual nitroglycerin use. Additional risk factors for hypotension may include concomitant use of other antihypertensive drugs or vasodilators or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Carefully monitor for signs and symptoms of postural hypotension (especially during dose escalation). Avoid ethanol during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have also been associated with fibrotic complications (eg, retroperitoneal fibrosis, pleural thickening, cardiac valvulopathy, and pulmonary infiltrates); monitor closely for signs and symptoms of fibrosis; effects may or may not be reversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Has been reported; severe priapism may require medical attention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Somnolence: Somnolence and falling asleep while engaging in activities of daily living, without prior warning signs, has been reported. Monitor for daytime somnolence or preexisting sleep disorder; caution with concomitant sedating medication; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; hypotension may cause coronary ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular disease: Use with caution in patients with cerebrovascular disease; hypotension may cause cerebral ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dyskinesias: Use with caution in patients with preexisting dyskinesias; may be exacerbated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; avoid use in severe hepatic impairment (sublingual film).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; avoid use in severe renal impairment (sublingual film).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (confusion and hallucinations), some serious, are reported more frequently in patients ≥65 years; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients at risk for torsades de pointes: Use with caution in patients with risk factors for torsades de pointes (hypokalemia, hypomagnesemia, bradycardia, concurrent use of drugs that prolong QTc, or genetic predisposition).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol: Injection may contain benzyl alcohol which has been associated with "gasping syndrome" in neonates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabisulfite: Contains metabisulfite, which may cause hypersensitivity reactions. Sensitivity to sulfites is more common in patients with asthma and may cause hypersensitivity reactions (including anaphylaxis and life-threatening asthma exacerbations).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sublingual film: Mild to moderate oral mucosal irritation (ulceration, stomatitis, pain, paresthesia) has occurred; usually resolved after discontinuation (rechallenge is not recommended).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse: Rare cases of abuse have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: Do not give SUBQ formulation IV; thrombus formation or pulmonary embolism may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome (eg, hyperpyrexia, confusion) on abrupt withdrawal or significant dosage reduction after long-term use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Falling: Patients with Parkinson disease are at risk of falling; apomorphine may increase this risk.</p></div>
<div class="block foc drugH1Div" id="F136165"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Sublingual, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kynmobi: 10 mg (30 ea [DSC]); 15 mg (30 ea [DSC]); 20 mg (30 ea [DSC]); 25 mg (30 ea [DSC]); 30 mg (30 ea [DSC]) [contains edetate (edta) disodium dihydrate, fd&amp;c blue #1 (brilliant blue), levomenthol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Sublingual, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kynmobi Titration Kit: 10 mg (2s), 15 mg (2s), 20 mg (2s), 25 mg (2s), 30 mg (2s) [DSC] [contains edetate (edta) disodium dihydrate, fd&amp;c blue #1 (brilliant blue), levomenthol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Apokyn: 30 mg/3 mL (3 mL) [contains benzyl alcohol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg/3 mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F136152"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16570476"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Apokyn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $591.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Apomorphine HCl Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $469.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865955"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Sublingual, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kynmobi: 10 mg ([DSC]); 15 mg ([DSC]); 20 mg ([DSC]); 25 mg ([DSC]); 30 mg ([DSC]) [contains edetate (edta) disodium dihydrate, fd&amp;c blue #1 (brilliant blue), levomenthol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Movapo: 10 mg/mL ([DSC])</p></div>
<div class="block accres drugH1Div" id="F11447031"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Apokyn is only available through specialty pharmacies and cannot be obtained through a retail pharmacy. For more information, contact 1-877-7APOKYN (1-877-727-6596).</p></div>
<div class="block adm drugH1Div" id="F136167"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sublingual film:</b> Do not remove from pouch until immediately before use. Drink water to moisten mouth, then place film under the tongue and allow to dissolve (~3 minutes). Do not talk or swallow saliva while dissolving because this can impact absorption. Administer whole; do not cut, chew, or swallow.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For SUBQ administration only; do not administer IV (thrombus formation or pulmonary embolism may occur due to IV crystallization). Administer in abdomen, upper arm, or upper leg; change site with each injection. Three mL cartridges are used with a manual, reusable, multidose injector pen. Injector pen can deliver up to 1 mL (10 mg) in 0.02 mL (0.2 mg) increments.</p></div>
<div class="block hazard drugH1Div" id="F49130879"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F136166"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual film: Treatment of acute, intermittent "off" episodes in patients with Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Treatment of acute, intermittent hypomobility "off" episodes in patients with advanced Parkinson disease.</p></div>
<div class="block cyt drugH1Div" id="F136196"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F136159"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hypotensive effect of Apomorphine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the hypotensive effect of Apomorphine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: May enhance the hypotensive effect of Apomorphine. Management: Patients taking apomorphine should lie down before and after taking sublingual nitroglycerin. Monitor blood pressure for hypotension and orthostatic hypotension when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F136171"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20547458"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if apomorphine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F136163"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Supine and standing BP and pulse (for SUBQ, monitor predose and 20-, 40-, and 60 minutes postdose with each test dose); signs and symptoms of hemolytic anemia; orthostatic hypotension; drowsiness or sleepiness; mental status and behavioral changes.</p></div>
<div class="block pha drugH1Div" id="F136154"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates postsynaptic D2-type receptors within the caudate putamen in the brain.</p></div>
<div class="block phk drugH1Div" id="F136169"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: SUBQ: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Sublingual: 3,630 L; SUBQ: 218 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not established; potential routes of metabolism include sulfation, N-demethylation, glucuronidation, and oxidation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Sublingual: ~1.7 hours (range: 0.8 to 3 hours); SUBQ: ~40 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Sublingual: 0.5 to 1 hour; SUBQ: 10 to 60 minutes.</p></div>
<div class="block phksp drugH1Div" id="F51220442"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: SUBQ: C<sub>max</sub> was increased by 50% in patients with moderate renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: SUBQ: C<sub>max</sub> was increased by 25% in patients with moderate hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F136173"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Dacepton</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Apomine | Apomorphine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Britaject</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Dacepton</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Apomorphin Neuraxpharm | Dacepton</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Apokinon | Apomorphine aguettant | Apomorphine biogaran | Apomorphine cooper | Apomorphine mylan | Apomorphine Renaudin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Apomorphine | Britaject</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Dacepton</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Britaject</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aposan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Apofin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aposan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apomorphin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apomorphin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Dacepton</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Apokyn | Apomorphine hydrocloride | Kynmobi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dacepton</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Britaject</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Dacepton</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apo go</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apo go | Epamor | Pargicyl | Parkoff</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aposan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Apokyn (apomorphine) [prescribing information]. Rockville, MD: MMD US Operations LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9316670">
<a name="9316670"></a>Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. <i>Clin Neuropharmacol</i>. 1994;17(3):243-259. doi:10.1097/00002826-199406000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/9316670/pubmed" id="9316670" target="_blank">9316670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18394561">
<a name="18394561"></a>Factor SA, “Current Status of Symptomatic Medical Therapy in Parkinson's Disease,” <i>Neurotherapeutics</i>, 2008, 5(2):164-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/18394561/pubmed" id="18394561" target="_blank">18394561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2313313">
<a name="2313313"></a>Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. <i>J Neurol Neurosurg Psychiatry</i>. 1990;53(2):96-101. doi:10.1136/jnnp.53.2.96<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/2313313/pubmed" id="2313313" target="_blank">2313313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kynmobi.1">
<a name="Kynmobi.1"></a>Kynmobi (apomorphine) sublingual film [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kynmobi.2">
<a name="Kynmobi.2"></a>Kynmobi (apomorphine) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11009192">
<a name="11009192"></a>Molina JA, Sàinz-Artiga MJ, Fraile A, et al, “Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,” <i>Mov Disord</i>, 2000, 15(5):869-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/11009192/pubmed" id="11009192" target="_blank">11009192</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Movapo (apomorphine) [product monograph]. St. Laurent, Quebec, Canada: Paladin Labs Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31818699">
<a name="31818699"></a>Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurol</i>. 2020;19(2):135-144. doi:10.1016/S1474-4422(19)30396-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/31818699/pubmed" id="31818699" target="_blank">31818699</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed June 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16831966">
<a name="16831966"></a>Weintraub D, Siderowf AD, Potenza MN, et al, “Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,” <i>Arch Neurol</i>, 2006, 63(7):969-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apomorphine-drug-information/abstract-text/16831966/pubmed" id="16831966" target="_blank">16831966</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9374 Version 295.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
